iotrolan has been researched along with Adverse Drug Event in 2 studies
iotrolan: nonionic, isotonic contrast medium designed for intrathecal use; RN given refers to cpd without isomeric designation; DL-3-117 refers to stereoisomer; structure given in first source
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kuwatsuru, R | 1 |
| Katayama, H | 1 |
| Riefke, B | 1 |
| González, L | 1 |
| Carretero, J | 1 |
| González, C | 1 |
| Jimenéz, I | 1 |
| Alguacil, LF | 1 |
| Böhle, F | 1 |
| Martin, F | 1 |
| Martin, JL | 1 |
2 other studies available for iotrolan and Adverse Drug Event
| Article | Year |
|---|---|
Evaluation of lotrolan after oral application to neonates, infants, and children: Japanese experience.
Topics: Adolescent; Child; Child, Preschool; Contrast Media; Drug-Related Side Effects and Adverse Reactions | 2002 |
ICJ 3393: a new lodinated nonionic low osmolal dimer with low viscosity as contrast agent for X-ray.
Topics: Animals; Contrast Media; Drug-Related Side Effects and Adverse Reactions; Kidney; Lethal Dose 50; Li | 2002 |